BioTuesdays
oramed

Oramed completes Phase 2b oral insulin study

Oramed Pharmaceuticals (NASDAQ:ORMP) said that all follow-up visits in its Phase 2b study of its oral insulin capsule, ORMD-0801, have been completed. The double-blind, randomized Phase 2b study of 180 patients with...

TransEnterix

TransEnterix updates SurgiBot FDA submission

TransEnterix (NYSE MKT:TRXC) has received an update from the FDA on the status of the 510(k) submission for its robotics SurgiBot system to improve minimally invasive surgery. The FDA advised the company that it has not...

TearLab

TearLab Q4 revenue climbs 28%

Fourth quarter revenue for TearLab (NASDAQ:TEAR; TSX:TLB) was $6.8-million, up 28% from $5.3-million a year ago. For all of 2015, revenue rose 28% to $25.2-million from $19.7-million for 2014. A net total of 258 TearLab...